Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129778 | 0.87 | TACR1 (0.38) | NPC1TACR1 | |
| SCHEMBL16094402 | 0.85 | TACR1 (0.42) | ALDH1A1HPGDCYP2D6NPC1KMT2A | |
| SCHEMBL16100257 | 0.84 | HRH3 (0.36) | ALDH1A1CYP3A4CYP2D6KMT2ATACR1 | |
| SCHEMBL16094151 | 0.84 | TACR1 (0.38) | ALDH1A1HPGDKDM4ECYP2D6NPC1 | |
| SCHEMBL16099794 | 0.82 | BTK (0.35) | ALDH1A1KDM4EKMT2ATACR1 | |
| SCHEMBL16129819 | 0.81 | ENPP2 (0.41) | ALDH1A1HPGDNPC1KMT2ATACR1 | |
| SCHEMBL16129709 | 0.81 | HPGD (0.39) | ALDH1A1HPGDKDM4ENPC1KMT2A | |
| SCHEMBL16099642 | 0.80 | TACR1 (0.39) | ALDH1A1HPGDNPC1KMT2ATACR1 | |
| SCHEMBL16102646 | 0.80 | ENPP2 (0.42) | ALDH1A1HPGDNPC1KMT2ATACR1 | |
| SCHEMBL16100235 | 0.79 | TACR1 (0.46) | ALDH1A1HPGDCYP2D6NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | ALDH1A1 4063/4885HPGD 3262/4885KDM4E 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.